• Skip to main content
  • Skip to footer

Akari Therapeutics

A Revolution in Treating Autoinflammatory & Orphan Diseases

Menu
  • HOME
  • ABOUT
    • Close
    • MANAGEMENT
    • BOARD OF DIRECTORS
  • LEAD INDICATIONS
    • Close
    • OVERVIEW
    • BP PIVOTAL
    • TMA-HSCT PIVOTAL
    • OPHTHALMIC CONDITIONS
    • PULMONARY CONDITIONS
    • PRECLINICAL PROGRAMS
      • Close
      • NOMACOPAN LA
      • VOTUCALIS
      • OTHER INDICATIONS
  • THE SCIENCE
    • Close
    • OVERVIEW
    • MODE OF ACTION
    • TARGET PATHWAYS
      • Close
      • C5 (COMPLEMENT SYSTEM)
      • LTB4 (LEUKOTRINE SYSTEM)
    • MOLECULES
      • Close
      • NOMACOPAN
      • OTHER NOMACOPAN-BASED MOLECULES
      • VOTUCALIS
  • INVESTOR RELATIONS
    • Close
    • OVERVIEW
    • GENERAL MEETING OF SHAREHOLDERS
    • FINANCIAL INFORMATION
      • Close
      • SEC FILINGS
      • ANNUAL REPORTS
    • NEWS & EVENTS
      • Close
      • PRESS RELEASES
      • EVENTS
      • PRESENTATIONS
    • STOCK INFORMATION
      • Close
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
      • INVESTMENT CALCULATOR
    • CORPORATE GOVERNANCE
      • Close
      • GOVERNANCE OVERVIEW
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • INVESTOR RESOURCES
      • Close
      • INVESTOR FAQS
      • EMAIL ALERTS
  • PRESS
    • Close
    • PRESS RELEASES
    • PUBLICATIONS
  • CONTACT US

Press Release

Akari TX / April 21, 2021

Akari Therapeutics Reports Full Year 2020 Financial Results and Highlights Recent Clinical Progress

‒ Opening of Investigational New Drug Application (IND) with U.S. Food and Drug Administration (FDA) for Phase III study of nomacopan in bullous pemphigoid …

[Read more...] about Akari Therapeutics Reports Full Year 2020 Financial Results and Highlights Recent Clinical Progress

Akari TX / April 12, 2021

Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP)

FDA investigational new drug application (IND) now open Clinical sites expected to open for recruitment mid-2021 NEW YORK and LONDON, …

[Read more...] about Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP)

Akari TX / March 4, 2021

Akari Therapeutics Announces a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) for Nomacopan in Trauma

Study of porcine model of blast injury and haemorrhagic shock underway with USAISR as part of the development of a clinical path for the use of nomacopan to …

[Read more...] about Akari Therapeutics Announces a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) for Nomacopan in Trauma

Akari TX / February 25, 2021

Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis

A newly published review article in the journal CELLS highlights the role LTB4 plays in the induction of vascular endothelial growth factor (VEGF) damage and …

[Read more...] about Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis

Akari TX / February 1, 2021

Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to treat Neuropathic Pain and Dermatological Disease

Building on the positive clinical and safety data from its lead drug nomacopan, Akari is developing a second related therapeutic candidate (votucalis) focusing …

[Read more...] about Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to treat Neuropathic Pain and Dermatological Disease

Next Page »

Footer

Akari TX

LONDON

75/76 Wimpole Street London W1G 9RT UK

T: +44 (0)20.8004.0261
E: info@Akaritx.com

NEW YORK

1460 Broadway
New York, NY 10036

T: 929.274.7510
F: 929.274.7553
E: info@Akaritx.com

For investor relations inquiries: IR@akaritx.com
For business development inquiries: BD@akaritx.com

EXPANDED ACCESS POLICY

In severe or life-threatening conditions where there are no available treatment options, regulators may grant permission to provide a treating physician access to an unapproved drug; this is known as expanded access.  At this time, the safety and effectiveness of nomacopan to treat diseases such as Atopic Keratoconjunctivitis (AKC), Bullous Pemphigoid (BP); Thrombotic Microangiopathy (TMA), and Paroxysmal Nocturnal Hemoglobinuria (PNH) has not been established. Until more data are available, Akari Therapeutics is not considering requests for expanded access outside of clinical trials. This policy may change as safety and efficacy are better demonstrated. For questions regarding our current expanded access policy, please contact Akari Therapeutics at +44 (0)20-8004-0261.

Copyright © 2021 · Akari Therapeutics · Site Designed by Polus Digital, Inc.